Goldman Sachs Lowers Price Target On Genzyme (GENZ); Maintains Sell
More News related to GENZ
- Trading Outlook for MannKind Corp. Issued by InvestorSoup.com
- Trading Outlook for Metabasis Therapeutics Issued by StockPreacher.com
- Trading Outlook for Incyte Corp. Issued by StockPreacher.com
- Trading Outlook for Elan Corp. Plc. Issued by InvestorSoup.com
- PTC Therapeutics Initiates Phase 2 Clinical Trial of ataluren (PTC124(R)) in Patients with Hemophilia
Goldman Sachs transfers coverage on Genzyme Corp. (Nasdaq: GENZ), maintaining a Sell rating and lowered their price target from $63 to $60. The new analyst cited no back-up manufacturing for Cerezyme and Fabrazyme, Lumizyme approval could further strain capacity, possible change in reimbursement from a health care reform bill.
For more analyst ratings on GENZ click here.
Genzyme Corporation operates as a biotechnology company worldwide.
Related Categories
Analyst CommentsStocks Mentioned
+0.26Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
